GPR137C Antibody

What is GPR137C and how does it differ from other GPR137 family members?

GPR137C is a member of the G protein-coupled receptor 137 family, which belongs to the larger superfamily of G protein-coupled receptors (GPCRs). While GPR137 has been extensively studied in cancer biology, GPR137C represents a distinct protein with potentially unique functions. Research has established that GPR137 family members are involved in signal transduction pathways across various tissues .

Unlike GPR137, which has been confirmed to participate in cancer progression through documented overexpression in bladder cancer tissues compared to adjacent normal tissues (mRNA expression level of 1.83 ± 0.33 versus 1 ± 0.09, P < .001) , the specific functions of GPR137C are still being elucidated. Methodologically, researchers should approach GPR137C studies with comparative analyses that include other family members to establish functional divergence or conservation.

What are the standard methods for detecting GPR137C expression in tissue samples?

Based on established protocols for GPR137 detection, researchers typically employ multiple complementary techniques:

• Quantitative Real-Time PCR (qRT-PCR): For mRNA expression analysis, using specific primers targeting GPR137C with appropriate housekeeping genes like GAPDH as internal controls. RNA extraction should follow standardized protocols using Trizol reagent, followed by DNase treatment to remove genomic DNA contamination .

• Western Blotting: For protein expression analysis, using validated GPR137C-specific antibodies. Protein should be extracted from tissues or cells using appropriate lysis buffers containing protease inhibitors .

• Immunohistochemistry (IHC): For tissue localization studies, using paraffin-embedded tissue sections (4-μm) with antigen retrieval. The standard protocol would include blocking with goat serum followed by overnight incubation with primary antibody (generally at 1:100 dilution) at 4°C .

When analyzing RNA integrity, 1% agarose gel electrophoresis should be performed to ensure 28S rRNA and 18S rRNA bands are clear with a brightness ratio close to 2:1 .

How should researchers validate the specificity of GPR137C antibodies?

Validation of GPR137C antibodies should follow a multi-step approach:

• Positive and negative control tissues: Use tissues known to express or lack GPR137C expression respectively.

• Blocking peptide competition: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining in Western blot or IHC.

• RNA interference validation: Compare antibody staining between cells with normal GPR137C expression and those where GPR137C has been knocked down using lentivirus-mediated RNAi approaches, similar to methods used for GPR137 validation .

• Recombinant protein controls: Test antibody reactivity against purified recombinant GPR137C protein at different concentrations.

• Cross-reactivity assessment: Evaluate potential cross-reactivity with other GPR137 family members through parallel staining of samples expressing different family members.

How can researchers differentiate between isoforms of GPR137C in experimental settings?

Differentiating between potential GPR137C isoforms requires specialized techniques based on approaches used for GPR137 isoform studies:

• Isoform-specific PCR primers: Design primers that span unique exon-exon junctions specific to each isoform. This approach was successfully used to distinguish between GPR137_Long and GPR137_Short isoforms in intestinal epithelial cells .

• RNA sequencing: Perform deep sequencing to identify all expressed isoforms and quantify their relative abundances in different tissues or experimental conditions.

• Targeted proteomic analysis: Develop mass spectrometry methods targeting unique peptides from each isoform. This requires:

  • Protein extraction and enzymatic digestion

  • Identification of isoform-specific peptides

  • Development of selected reaction monitoring (SRM) methods

• Isoform-specific antibodies: Generate antibodies targeting unique regions of specific isoforms, followed by rigorous validation using overexpression systems.

Research on GPR137 has demonstrated that different isoforms (GPR137_Long versus GPR137_Short) exhibited distinct functional properties in intestinal epithelial cells, affecting proliferation rates and epithelial barrier formation . This suggests that potential GPR137C isoforms might similarly display functional diversity.

What are the recommended experimental designs for studying GPR137C function in cancer models?

Based on successful approaches studying the related GPR137, researchers should consider:

• Expression profiling across cancer types:

  • Compare GPR137C expression in tumor tissues versus adjacent normal tissues using qRT-PCR and IHC

  • Correlate expression with clinicopathological features (tumor size, stage, etc.)

  • Perform survival analysis stratified by GPR137C expression levels

• Loss-of-function studies:

  • Develop lentivirus-mediated RNAi systems targeting GPR137C

  • Assess effects on:

    • Cell proliferation (using cell counting, MTT assays)

    • Colony formation capacity

    • Cell cycle distribution (flow cytometry)

    • Apoptosis (Annexin V/7-AAD staining)

    • Expression of cell cycle regulators (CyclinD1, CDK4) and apoptosis mediators (BCL-2, caspase-3)

• Gain-of-function studies:

  • Generate stable cell lines overexpressing GPR137C

  • Assess changes in cellular phenotypes and molecular pathways

• In vivo models:

  • Xenograft models with GPR137C-modulated cancer cells

  • Genetically engineered mouse models with tissue-specific GPR137C alterations

Studies of GPR137 in leukemia demonstrated that lentivirus-mediated RNAi significantly downregulated gene and protein expression, leading to reduced proliferation, colony formation capacity, cell cycle arrest in G0/G1 phase, and increased apoptosis .

How should researchers address potential data contradictions when studying GPR137C in different tumor types?

When facing contradictory data regarding GPR137C across different tumor types, researchers should:

• Consider tissue-specific effects:

  • GPR137 has shown diverse roles across different cancers, suggesting its family members might demonstrate context-dependent functions

  • Analyze tissue-specific expression patterns and interacting partners

• Assess experimental methodology differences:

  • Standardize key experimental parameters across studies

  • Compare antibody specificities and validation methods

  • Evaluate cell line authenticity and passage numbers

• Integrate multi-omics approaches:

  • Combine transcriptomic, proteomic, and functional data

  • Perform pathway enrichment analyses to identify context-specific molecular networks

• Analyze potential isoform differences:

  • Different tissues may express distinct GPR137C isoforms with varying functions

  • GPR137 research has shown that different isoforms can have opposing effects on cellular processes

• Statistical considerations:

  • Perform meta-analyses when multiple studies are available

  • Calculate effect sizes rather than relying solely on p-values

  • Consider publication bias when interpreting literature

How can GPR137C antibodies be utilized in cancer biomarker studies?

Based on findings from GPR137 research, GPR137C antibodies could be applied in cancer biomarker studies through:

• Tissue microarray analysis:

  • Systematically evaluate GPR137C expression across multiple tumor samples

  • Correlate with clinical outcomes and pathological features

  • Compare with established biomarkers

• Prognostic value assessment:

  • Perform Kaplan-Meier survival analyses stratified by GPR137C expression

  • Conduct multivariate Cox regression analysis to determine independent prognostic value

• Liquid biopsy applications:

  • Develop methods to detect soluble GPR137C or GPR137C-expressing exosomes in patient serum

  • Evaluate as a potential non-invasive biomarker

What methodologies are recommended for investigating GPR137C signaling pathways?

To elucidate GPR137C signaling mechanisms, researchers should consider:

• Interactome analysis:

  • Perform co-immunoprecipitation followed by mass spectrometry

  • Conduct yeast two-hybrid screening

  • Implement proximity labeling techniques (BioID, APEX)

• Signaling pathway interrogation:

  • Analyze activation of canonical GPCR pathways (G-protein dependent and independent)

  • Monitor second messenger levels (cAMP, calcium, etc.)

  • Assess β-arrestin recruitment and downstream effects

• Transcriptional response:

  • Perform RNA-seq after GPR137C modulation

  • Identify direct transcriptional targets

  • Conduct pathway enrichment analysis

• Phosphoproteomic analysis:

  • Map phosphorylation changes upon GPR137C activation or inhibition

  • Identify key kinases involved in signal transduction

Research on the related GPR137 has identified connections to the Wnt signaling pathway, with different isoforms showing varying capacities to activate this pathway in intestinal epithelial cells . Similar pathway analysis approaches could reveal GPR137C-specific signaling mechanisms.

How might GPR137C contribute to intestinal pathology based on findings from related family members?

Given the established role of GPR137 in intestinal pathophysiology, GPR137C might contribute to intestinal disorders through similar mechanisms:

• Epithelial barrier function:

  • Investigate GPR137C effects on intestinal epithelial cell tight junctions

  • Assess transepithelial electrical resistance in GPR137C-modulated cell monolayers

  • Evaluate paracellular permeability using fluorescent tracers

• Inflammatory bowel disease connection:

  • Analyze GPR137C expression in IBD patient biopsies compared to healthy controls

  • Investigate correlations with disease activity and inflammatory markers

  • Assess potential genetic associations

• Colorectal cancer progression:

  • Examine stage-dependent expression changes

  • Evaluate contribution to epithelial-mesenchymal transition

  • Investigate interactions with established oncogenic pathways

Research has shown that ESRP1-regulated GPR137 isoforms play critical roles in intestinal homeostasis, with altered isoform expression contributing to inflammatory bowel disease and colorectal cancer pathogenesis. Mechanistically, these effects were mediated in part by differential activation of the Wnt pathway by specific GPR137 isoforms .